Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades9,841
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions1
GSK
Media
GSK Company
Research
GSK Company
Timeline1
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
1,913.00
-25.00 (-1.29%)
Bid:
1,917.00
Ask:
1,918.00
Spread:
1.00 (0.052%)
Market Cap:
£76.72b
Last checked at -
Last checked at 
Intraday Glaxosmithkline Share Chart
Glaxosmithkline News
6 Aug 2025
UK stocks rise as investors assess corporate results ahead of BoE rate decision
FTSE 100 up 0.2%, FTSE 250 up 0.1% *
1 Aug 2025
Pharma drags London stocks lower after Trump's tariff blitz
FTSE 100 down 0.7%, FTSE 250 falls 1.2% *
1 Aug 2025
London close: Stocks fall on Trump's latest tariffs, US jobs data
(Sharecast News) - London stocks ended the week lower on Friday as investors reacted to a fresh wave of US tariffs and disappointing economic data fro...
1 Aug 2025
LONDON MARKET CLOSE: Stocks rocked by tariffs and weak US jobs print
(Alliance News) - The FTSE 100 sank on Friday after US President Donald Trump announced tariffs on dozens of trading partners, and weak US jobs data f...
1 Aug 2025
Pharma drags London stocks lower after Trump's tariff blitz
FTSE 100 down 0.7%, FTSE 250 down about 1% *
1 Aug 2025
LONDON BROKER RATINGS: Taylor Wimpey, Pets At Home, Just Group are cut
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday:
1 Aug 2025
European drugmakers fall after Trump raises stakes over US drug price cuts
Trump demands drugmakers match US prices to overseas levels *
31 Jul 2025
UK's Haleon cuts revenue growth forecast on weak North America demand
FY organic revenue growth now expected around 3.5% *
Follow the stocks
